相关实验视频

Updated: Jul 15, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

在小鼠中,丁治疗对葡萄糖代谢的急性刺激

S Kamohara¹, R Burcelin, J L Halaas

¹Laboratory of Molecular Genetics, the Rockefeller University, New York 10021, USA.

|October 6, 1997

概括

瘦素是一种调节体重的激素,急剧增强葡萄糖代谢. 这种在输入莱普后观察到的效应表明中枢神经系统的调解,并影响葡萄糖和脂质代谢.

科学领域:

内分泌学在内分泌学.
代谢研究研究代谢研究
神经科学是一个神经科学.

背景情况:

瘦素是通过负反循环调节体重的关键激素.
素与下丘脑受体相互作用,影响食欲和能量消耗.
关于叶黄素代谢作用的先前研究被其减肥特性所迷惑.

研究的目的:

为了研究丁对葡萄糖代谢的急性影响,独立于体重变化.
为了确定叶黄素对葡萄糖代谢的影响是否由中枢神经系统 (CNS) 介导.

主要方法:

给野生类型小鼠静脉和脑内静脉注射丁.
在5小时内监测葡萄糖周转,葡萄糖吸收,肝脏糖原含量和血胰岛素/葡萄糖水平.
中心与外围丁的效果比较.

主要成果:

丁输注显著增加了葡萄糖的循环和吸收.
在服用莱普后,肝脏糖原含量下降.
血胰岛素和葡萄糖水平保持不变,中央管理模仿了外围影响.

结论:

莱普急性刺激葡萄糖代谢,表明其作用超出了长期体重调节的范围.
中枢神经系统在调解莱普对葡萄糖代谢的急性影响方面发挥着至关重要的作用.
莱普引起一种独特,复杂的代谢反应,涉及葡萄糖和脂质通路,这表明中枢神经系统的新型传递信号.

更多相关视频

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

相关概念视频

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...